In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...

Scarlett, a retired thoroughbred racehorse and descendant of Secretariat, has become like family for Jenna and her parents, Kim and Matt.

A new research paper was published in , Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters' model: A regenerative approach using ...

Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with ...

Mean dose to the tongue mucosa did not improve predictions of taste impairment during and after radiation therapy compared ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Leukopenia, weight loss and oral ...

HPV causes irritating warts, or lesions, on the back, front, or side of the tongue. Males have a higher risk of developing ...

Cancer patients undergoing chemotherapy or radiotherapy often experience 'chemo mouth,' with painful symptoms like mouth ...

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...